Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Specific HIV Protease Inhibitors Inhibit the Ability of Hpv16 E6 to Degrade P53 and Selectively Kill E6-Dependent Cervical Carcinoma Cells In Vitro

1 Aug 2006

Abstract excerpt

Although HIV protease inhibitor (PI) drugs predominantly target HIV proteases 1 and 2, it is also known that part of their efficacy is due to selective inhibition of the proteasome. The pathogenicity of high-risk human papilloma virus (HPV) is dependent on expression of viral E6 proteins which inappropriately activate the 26S proteasome to degrade p53 and other cellular proteins that are detrimental to viral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cervical Cancer and HPV Research
Share to Hepatitis B Virus Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17310826
DOI: 10.1177/135965350601100607

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Specific HIV Protease Inhibitors Inhibit the Ability of Hpv16 E6 to Degrade P53 and Selectively Kill E6-Dependent Cervical Carcinoma Cells In VitroPMID 17310826Read ↗

Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor ActivitiesSemantic proximity Read ↗

Anticancer Drugs Aimed at E6 and E7 Activity in HPV-Positive Cervical CancerSemantic proximity Read ↗

The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status.Semantic proximity Read ↗

Degradation of p53 by Human Alphapapillomavirus E6 Proteins Shows a Stronger Correlation with Phylogeny than OncogenicitySemantic proximity Read ↗

Small Molecule Inhibitors of Human Papillomavirus Protein - Protein InteractionsSemantic proximity Read ↗

Identification and Characterization of Small Molecule Human Papillomavirus E6 InhibitorsSemantic proximity Read ↗

Differential regulation of cutaneous oncoprotein HPVE6 by wtp53, mutant p53R248W and ΔNp63α is HPV type dependent.Semantic proximity Read ↗

Comparative Analysis of 19 Genital Human Papillomavirus Types with Regard to p53 Degradation, Immortalization, Phylogeny, and Epidemiologic Risk ClassificationSemantic proximity Read ↗

Activation of p53 in cervical carcinoma cells by small moleculesSemantic proximity Read ↗

Isolation and functional analysis of five HPVE6 variants with respect to p53 degradation.Semantic proximity Read ↗

Degradation of p53 by HPV16-E6 variants isolated from cervical cancer specimens of Moroccan women.Semantic proximity Read ↗

Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.